Concordance Between Clinician-Reported and Patient-Reported Outcomes of Eyebrow and Eyelash Hair Loss in Patients With Severe Alopecia Areata: Results From BRAVE-AA1 and BRAVE-AA2 Studies

June 2024 in “ Journal of the American Academy of Dermatology ”

Arash Mostaghimi, Justin Ko, Antonellá Tosti, Amy McMichael, Manabu Ohyama, Taisuke Ito, Yves Dutronc, Susan Ball, Guanglei Yu, Mwangi J. Murage, Yun-Fei Chen, Chiara Chiasserini, Andreas Wollenberg

alopecia areata eyebrow hair loss eyelash hair loss ClinRO PRO BRAVE-AA1 BRAVE-AA2 patient-reported outcomes clinician-reported outcomes

TLDR Patients and clinicians generally agree on eyebrow and eyelash hair loss improvements in severe alopecia areata.

The study evaluated the concordance between clinician-reported outcomes (ClinRO) and patient-reported outcomes (PRO) for eyebrow and eyelash hair loss in 1,191 patients with severe alopecia areata over 52 weeks, using data from the BRAVE-AA1 and BRAVE-AA2 phase 3 studies. Strong positive correlations were found between ClinRO and PRO measures for both eyebrows and eyelashes at baseline, Week 36, and Week 52, with Spearman's rank correlation coefficients ranging from 0.83 to 0.87. Concordance rates were highest for scores indicating no notable hair (3) and full coverage (0), while scores 1 and 2 showed lower concordance, possibly due to clinicians' unfamiliarity with patients' normative appearance. Overall, more than 75% of patients agreed with clinicians on ≥1-point improvement, and approximately 87%-89% agreed on ≥2-point improvement from baseline in both eyebrows and eyelashes by Week 52. These findings suggest that patient assessments using PROs align closely with clinician assessments.

View this study on doi.org →

Discuss this study in the Community →

Research cited in this study

2 / 2 results

research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials

20 citations , March 2023 in “American Journal of Clinical Dermatology”

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

research Development of Clinician-Reported Outcome and Patient-Reported Outcome Measures for Eyebrow, Eyelash, and Nail Assessment in Alopecia Areata

56 citations , August 2020 in “American Journal of Clinical Dermatology”

New tools help assess eyebrow, eyelash, and nail changes in Alopecia Areata, improving understanding of patient experiences.

Related Community Posts Join

6 / 1000+ results

community 27m oral min and fin results after 5 months.

in Progress Pictures 336 upvotes 3 years ago

Hair loss treatments and the user's progress with taking finasteride and minoxidil orally, which has resulted in full recovery after 5 months. Users commented on this progress and discussed their own experiences or confusion about the treatments used.

community Actor Jacob Batalon, 26, has a receding hairline. I thought it was pretty cool to see a younger actor being successful, despite dealing with hair loss. His most well known role is Ned Leeds in the Marvel Cinematic Universe, and he is currently the CEO of Sex.

in Satire 498 upvotes 2 years ago

Actor Jacob Batalon's receding hairline and how it is a sign of his success despite dealing with hair loss, with some people suggesting he may be using treatments such as Minoxidil or Finasteride to manage it.

community Rare Non responder to Finasteride, Dutasteride, and oral minoxidil

in Minoxidil 78 upvotes 1 year ago

A user did not respond to finasteride, dutasteride, and oral minoxidil for hair loss after four years of treatment and is considering scalp micropigmentation (SMP). Other users suggest the hair loss pattern may indicate alopecia areata and recommend seeing a dermatologist.

community If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied

in Research 830 upvotes 1 year ago

Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

community Any experience with Latanoprost?

in Product 6 upvotes 3 years ago

Hair loss discussion includes Latanoprost as potential treatment. Mild improvement observed with its use.

community Why is no one pointing out dandruff as the number 1 evidence/symptom of MPB?

in Chat 55 upvotes 2 years ago

The post discusses the theory that persistent dandruff in areas prone to hair loss could be a sign of hair follicles dying due to DHT, indicating balding. The responses vary, with some users noting improvements in dandruff and hair loss with treatments like Dutasteride, while others experienced hair loss without dandruff.

Related Research

3 / 3 results

research Baseline Distribution of Eyebrow and Eyelash Loss by Severity of Scalp Hair Loss in Phase 3 Trials of Baricitinib for Alopecia Areata

September 2023 in “Journal of The American Academy of Dermatology”

The document's conclusion cannot be provided because the content is not available.

research Baricitinib Results in Eyebrow and Eyelash Growth in Patients With Alopecia Areata Who Do Not Achieve 20% or Less Scalp Hair Loss

1 citations , September 2022 in “Journal of The American Academy of Dermatology”

Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.

Review of Representative Trichoscopic Findings in Androgenetic and Alopecia Areata Patients Visiting Dermatology Outpatient Clinic at University Hospital

research Review of Representative Trichoscopic Findings in Androgenetic and Alopecia Areata Patients Visiting Dermatology Outpatient Clinic at University Hospital

November 2016 in “대한피부과학회지”

The document's conclusion cannot be summarized as it is not provided in a language I can understand.